{
    "clinical_study": {
        "@rank": "29922", 
        "arm_group": [
            {
                "arm_group_label": "Experimental Icotinib", 
                "arm_group_type": "Experimental", 
                "description": "Icotinib: 125mg, oral administration, three times per day."
            }, 
            {
                "arm_group_label": "Chemotherapy Regimen 1", 
                "arm_group_type": "Active Comparator", 
                "description": "Chemotherapy Regimen 1\uff1aPemetrexe 500 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity."
            }, 
            {
                "arm_group_label": "Chemotherapy Regimen 2", 
                "arm_group_type": "Active Comparator", 
                "description": "Chemotherapy Regimen 2\uff1aDocetaxel 75 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to compare the efficacy and safety of first-line icotinib treatment\n      and first-line chemotherapy followed by maintenance treatment with icotinib."
        }, 
        "brief_title": "Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "EGFR Positive Non-small Cell Lung Cancer", 
            "Adenocarcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is designed to compare the efficacy and safety of first-line icotinib treatment\n      and first-line chemotherapy followed by maintenance with icotinib.\n\n      Primary endpoint:\n\n      Progression-free survival between first-line icotinib treatment and first-line chemotherapy\n      followed by maintenance with icotinib\n\n      Secondary endpoint:\n\n        1. Overall survival between icotinib and chemotherapy\n\n        2. Time to Progression between icotinib and chemotherapy\n\n        3. Objective response rate and disease control rate between icotinib and chemotherapy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologic confirmation of lung adenocarcinoma with measurable disease, defined as at\n             least one lesion that can be accurately measured in at least one dimension (longest\n             diameter to be recorded on CT); Patients must have previously untreated locally\n             advanced or metastatic NSCLC; Patients must have lung cancer with a documented EGFR\n             activating mutation (exon 19 deletion, L858R).\n\n        Exclusion Criteria:\n\n          -  Prior chemotherapy Prior treatment with gefitinib, erlotinib, or other drugs that\n             target EGFR Patients must not be receiving any other investigational agents Any\n             evidence of interstitial lung disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01665417", 
            "org_study_id": "BD-IC-IV08"
        }, 
        "intervention": [
            {
                "arm_group_label": "Experimental Icotinib", 
                "description": "Icotinib: 125mg, oral administration, three times per day.", 
                "intervention_name": "Experimental", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BPI-2009", 
                    "Commana"
                ]
            }, 
            {
                "arm_group_label": [
                    "Chemotherapy Regimen 1", 
                    "Chemotherapy Regimen 2"
                ], 
                "description": "Chemotherapy Regimen 1\uff1aPemetrexe 500 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.", 
                "intervention_name": "Chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Pemetrexe", 
                    "ALIMTA"
                ]
            }, 
            {
                "arm_group_label": [
                    "Chemotherapy Regimen 1", 
                    "Chemotherapy Regimen 2"
                ], 
                "description": "Chemotherapy Regimen 2\uff1aDocetaxel 75 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.", 
                "intervention_name": "Chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Docetaxel", 
                    "Taxotere"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Icotinib", 
            "EGFR positive mutation", 
            "First-line treatment", 
            "Maintenance treatment"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "contact": {
                "last_name": "Jiao Shunchang, MD", 
                "phone": "0086-13801380677"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100853"
                }, 
                "name": "Chinese People's Liberation Army (PLA) General Hospital"
            }, 
            "investigator": {
                "last_name": "Jiao Shunchang, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma", 
        "overall_contact": {
            "last_name": "Jiao Shunchang, MD", 
            "phone": "0086-13801380677"
        }, 
        "overall_official": [
            {
                "affiliation": "Chinese People's Liberation Army (PLA) General Hospital", 
                "last_name": "Jiao Shunchang, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Beijing Cancer Hospital", 
                "last_name": "Fang Jian, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Peking Union Medical College Hospital", 
                "last_name": "Bai Chunmei, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Hebei Provincal Tumor Hospital", 
                "last_name": "Liu Wei, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PFS was defined as the time from the date of first dose of study medication to the date of first documentation of tumor progression or death due to any cause, whichever occurred first.", 
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "8 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01665417"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "OS was assessed via calculation of the time to death due to any cause from the date of randomization. A patient was censored at the last date they were known to be alive.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "TTP was defined as the time from the date of first dose of study medication to first documentation of objective tumor progression. If tumor progression data included more than 1 date, the first date was used. TTP (in weeks) was calculated as (first event date minus first dose date +1)/7. Kaplan-Meier method was used.", 
                "measure": "Time to Tumor Progression", 
                "safety_issue": "No", 
                "time_frame": "8 months"
            }, 
            {
                "description": "Number of Subjects With Overall Confirmed Objective Disease Response According to the Response Evaluation Criteria in Solid Tumors(RECIST)1.1.", 
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Adverse events assessed by CTCAE4.0.", 
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Betta Pharmaceuticals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Betta Pharmaceuticals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}